Molecular Changes in pp32 in Prostate Cancer
Abstract
Our previous work demonstrated that prostate cancers differ from benign prostatic epithelium in their expression of oncogenic members of the pp32 gene family. Whereas benign prostatic epithelium solely expresses pp32, a tumor suppressor, prostate cancers express pp32rl and pp32r2, which are oncogenic. The purpose of the study is to confirm and extend these preliminary results, to develop practical means to assay pp32 gene family members in clinical samples, and to determine the clinical significance of their presence. The approved proposal encompassed four broad tasks: 1 characterization of the pp32 expression phenotype of a larger sample of 40 prostatic adenocarcinomas; 2 development of a practical molecular pathology assay for altered pp32 transcripts; 3 adaptation of the assay to paraffin-embedded tissue; and 4 preliminary determination of the clinical utility of pp32rl and pp32r2 expression in prostatic adenocarcinoma. In the course of pursuing this work, we recognized that improved assay methods would yield better results for Task 1. We have completed development of a robust and practical molecular assay (Task 2) and have nearly completed Task 3, adaptation to paraffin. In the remaining funding period, these tools shall be applied to completion of Task 1 and Task 4.
Document Details
- Document Type
- Technical Report
- Publication Date
- Sep 01, 2000
- Accession Number
- ADA392425
Entities
People
- Gary R. Pasternack
Organizations
- Johns Hopkins University